1
|
Liu L, Zhao N, Yang K, Liao H, Liu X, Wu Y, Wang Y, Peng X, Wu Y. Proteomic Analysis of Staphylococcus aureus Treated with ShangKeHuangShui. Biol Pharm Bull 2024; 47:292-302. [PMID: 38281773 DOI: 10.1248/bpb.b23-00471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2024]
Abstract
Staphylococcus aureus (SAU) stands as the prevailing pathogen in post-traumatic infections, with the emergence of antibiotic resistance presenting formidable treatment hurdles. The pressing need is to explore novel antibiotics to address this challenge. ShangKeHuangShui (SKHS), a patented traditional Chinese herbal formula, has gained widespread use in averting post-traumatic infections, but its biological effects remain incomplete understanding. This study's primary objective was to delve into the antibacterial properties, potential antibacterial compounds within SKHS, and their associated molecular targets. In vitro SKHS antibacterial assays demonstrated that the minimum inhibitory concentration (MIC) was 8.625 mg/mL and the minimum bactericide concentration (MBC) was 17.25 mg/mL. Proteomic analysis based on tandem mass tag (TMT) showed significant changes in the expression level of 246 proteins in SKHS treated group compared to control group, with 79 proteins upregulated and 167 proteins downregulated (>1.5-fold, p < 0.05). Subsequently, thirteen target proteins related to various biological processes and multiple metabolic pathways were selected to conduct parallel reaction monitoring (PRM) and molecular docking screen. In protein tyrosine phosphatase PtpA (ptpA) docking screening, phellodendrine and obacunone can bind to ptpA with the binding energy of - 8.4 and - 8.3 kcal/mol, respectively. This suggests their potential impact on antibacterial activity by modulating the two-component system of SAU. The discovery lays a groundwork for future research endeavors for exploring new antibacterial candidates and elucidating specific active chemical components within SKHS that match target proteins. Further investigations are imperative to unveil the biological effects of these monomers and their potential synergistic actions.
Collapse
Affiliation(s)
- Lichu Liu
- Institute of Orthopedics and Traumatology, Foshan Hospital of Traditional Chinese Medicine
| | - Na Zhao
- Institute of Orthopedics and Traumatology, Foshan Hospital of Traditional Chinese Medicine
| | - Kuangyang Yang
- Institute of Orthopedics and Traumatology, Foshan Hospital of Traditional Chinese Medicine
| | - Honghong Liao
- Institute of Orthopedics and Traumatology, Foshan Hospital of Traditional Chinese Medicine
| | - Xiaofang Liu
- Institute of Orthopedics and Traumatology, Foshan Hospital of Traditional Chinese Medicine
| | - Ying Wu
- Laboratory Medicine Center, Foshan Hospital of Traditional Chinese Medicine
| | - Yan Wang
- Center for Translational Medicine Research and Development, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences
| | - Xiao Peng
- Institute of Orthopedics and Traumatology, Foshan Hospital of Traditional Chinese Medicine
| | - Yuanyan Wu
- Institute of Orthopedics and Traumatology, Foshan Hospital of Traditional Chinese Medicine
| |
Collapse
|
2
|
Li M, Tian F, Guo J, Li X, Ma L, Jiang M, Zhao J. Therapeutic potential of Coptis chinensis for arthritis with underlying mechanisms. Front Pharmacol 2023; 14:1243820. [PMID: 37637408 PMCID: PMC10450980 DOI: 10.3389/fphar.2023.1243820] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2023] [Accepted: 08/01/2023] [Indexed: 08/29/2023] Open
Abstract
Arthritis is a common degenerative disease of joints, which has become a public health problem affecting human health, but its pathogenesis is complex and cannot be eradicated. Coptis chinensis (CC) has a variety of active ingredients, is a natural antibacterial and anti-inflammatory drug. In which, berberine is its main effective ingredient, and has good therapeutic effects on rheumatoid arthritis (RA), osteoarthritis (OA), gouty arthritis (GA). RA, OA and GA are the three most common types of arthritis, but the relevant pathogenesis is not clear. Therefore, molecular mechanism and prevention and treatment of arthritis are the key issues to be paid attention to in clinical practice. In general, berberine, palmatine, coptisine, jatrorrhizine, magnoflorine and jatrorrhizine hydrochloride in CC play the role in treating arthritis by regulating Wnt1/β-catenin and PI3K/AKT/mTOR signaling pathways. In this review, active ingredients, targets and mechanism of CC in the treatment of arthritis were expounded, and we have further explained the potential role of AHR, CAV1, CRP, CXCL2, IRF1, SPP1, and IL-17 signaling pathway in the treatment of arthritis, and to provide a new idea for the clinical treatment of arthritis by CC.
Collapse
Affiliation(s)
- Mengyuan Li
- Haihe Laboratory of Modern Chinese Medicine, Tianjin, China
| | - Fei Tian
- Haihe Laboratory of Modern Chinese Medicine, Tianjin, China
- National Key Laboratory of Chinese Medicine Modernization, Tianjin University of Traditional Chinese Medicine, Tianjin, China
| | - Jinling Guo
- Haihe Laboratory of Modern Chinese Medicine, Tianjin, China
| | - Xiankuan Li
- School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, China
| | - Lin Ma
- School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, China
| | - Miaomiao Jiang
- Haihe Laboratory of Modern Chinese Medicine, Tianjin, China
- National Key Laboratory of Chinese Medicine Modernization, Tianjin University of Traditional Chinese Medicine, Tianjin, China
| | - Jing Zhao
- Haihe Laboratory of Modern Chinese Medicine, Tianjin, China
- Department of Geriatric, Fourth Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
| |
Collapse
|
3
|
Yang K, Xie Q, Liang J, Shen Y, Li Z, Zhao N, Wu Y, Liu L, Zhang P, Hu C, Chen L, Wang Y. Identification of Andrographolide as a novel FABP4 inhibitor for osteoarthritis treatment. PHYTOMEDICINE : INTERNATIONAL JOURNAL OF PHYTOTHERAPY AND PHYTOPHARMACOLOGY 2023; 118:154939. [PMID: 37354697 DOI: 10.1016/j.phymed.2023.154939] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/24/2023] [Revised: 05/30/2023] [Accepted: 06/19/2023] [Indexed: 06/26/2023]
Abstract
BACKGROUND AND PURPOSE Fatty acid binding protein 4 (FABP4) has been identified as a contributor to cartilage degradation in osteoarthritis (OA) patients, and inhibiting FABP4 using small molecules has emerged as a promising approach for developing OA drugs. Our previous research showed that Andrographis paniculata, a medicinal plant, strongly inhibits FABP4 activity. This led us to hypothesize that Andrographis paniculata ingredients might have protective effects on OA cartilage through FABP4 inhibition. METHODS We analyzed scRNA-seq data from joint tissue of OA patients (GSE152805; GSE145286) using Scanpy 1.9.1 and Single Cell Portal. We conducted docking analysis of FABP4 inhibitors using Autodock Vina v.1.0.2. We evaluated the anti-FABP4 activity using a fluorescence displacement assay and measured the fatty acid oxidation (FAO) activity using the FAOBlue assay. We used H2DCF-DA to measure reactive oxygen species (ROS) levels. We studied signaling pathways using bulk RNA sequencing and western blot analysis in human C28/I2 chondrocytes. We evaluated anti-OA activity in monosodium iodoacetate (MIA)-induced rats. RESULTS We identified Andrographolide (AP) as a novel FABP4 inhibitor. Bulk RNA-sequencing analysis revealed that FABP4 upregulated FAO and ROS in chondrocytes, which was inhibited by AP. ROS generation activated the NF-κB pathway, leading to overexpression of a disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS4), which is a responsible factor for cartilage degradation in OA patients. AP inhibited FABP4, thereby reducing the overexpression of ADAMTS4 by inhibiting the NF-κB pathway. In MIA rats, AP treatment reduced the overexpression of ADAMTS4, repaired cartilage and subchondral bone, and promoted cartilage regeneration. CONCLUSION Our results indicate that the inhibition of FABP4 activity by AP explains the anti-OA properties of Andrographis paniculata by protecting against cartilage degradation in OA patients. Additionally, our findings suggest that AP may be a promising therapeutic agent for OA treatment due to its ability to alleviate cartilage damage and bone erosion.
Collapse
Affiliation(s)
- Kuangyang Yang
- Foshan Hospital of Traditional Chinese Medicine, Institute of Orthopedics and Traumatology, Foshan 528000, China
| | - Qian Xie
- Center for Translation Medicine Research and Development, Chinese Academy of Sciences, Shenzhen Institutes of Advanced Technology, Shenzhen 518055, China; Department of Orthopaedics, Shenzhen University General Hospital, Shenzhen 518055, China
| | - Jianhui Liang
- Center for Translation Medicine Research and Development, Chinese Academy of Sciences, Shenzhen Institutes of Advanced Technology, Shenzhen 518055, China
| | - Yanni Shen
- Center for Translation Medicine Research and Development, Chinese Academy of Sciences, Shenzhen Institutes of Advanced Technology, Shenzhen 518055, China; Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China
| | - Ziqi Li
- Center for Translation Medicine Research and Development, Chinese Academy of Sciences, Shenzhen Institutes of Advanced Technology, Shenzhen 518055, China
| | - Na Zhao
- Foshan Hospital of Traditional Chinese Medicine, Institute of Orthopedics and Traumatology, Foshan 528000, China
| | - Yuanyan Wu
- Foshan Hospital of Traditional Chinese Medicine, Institute of Orthopedics and Traumatology, Foshan 528000, China
| | - Lichu Liu
- Foshan Hospital of Traditional Chinese Medicine, Institute of Orthopedics and Traumatology, Foshan 528000, China
| | - Peng Zhang
- Center for Translation Medicine Research and Development, Chinese Academy of Sciences, Shenzhen Institutes of Advanced Technology, Shenzhen 518055, China
| | - Chun Hu
- Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China
| | - Lei Chen
- School of Life Science and Technology, Key Laboratory of Developmental Genes and Human Disease, Southeast University, Nanjing 210096, China
| | - Yan Wang
- Center for Translation Medicine Research and Development, Chinese Academy of Sciences, Shenzhen Institutes of Advanced Technology, Shenzhen 518055, China.
| |
Collapse
|